ArticleGene therapy2011
Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device.
Article in Gene therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 62 citations in OpenAlex.
- Safety and tolerability of the Easy Vax™ clinical epidermal electroporation system in healthy adults.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Trial
- Plasmid DNA Delivery into the Skin via Electroporation with a Depot-Type Electrode.Pharmaceutics · 2024Article
- Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation.Molecular therapy. Nucleic acids · 2023Article
- Moderate Heat-Assisted Gene Electrotransfer as a Potential Delivery Approach for Protein Replacement Therapy through the Skin.Pharmaceutics · 2021Article
- DNA vaccines: prime time is now.Current opinion in immunology · 2020Review
- Coalesced thermal and electrotransfer mediated delivery of plasmid DNA to the skin.Bioelectrochemistry (Amsterdam, Netherlands) · 2019Article
- Safe and efficient novel approach for non-invasive gene electrotransfer to skin.Scientific reports · 2018Article
- DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.Human vaccines & immunotherapeutics · 2017Article
- Adipose tissue: a new target for electroporation-enhanced DNA vaccines.Gene therapy · 2017Article
- Article
- Characterization of guinea pig T cell responses elicited after EP-assisted delivery of DNA vaccines to the skin.Vaccine · 2017Article
- Article
- Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge.Mucosal immunology · 2016Article
- Thermal Assisted In Vivo Gene Electrotransfer.Current gene therapy · 2016Article
- An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.Journal of virology · 2015Article
- Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.Human gene therapy methods · 2015Article
- Application of increased temperature from an exogenous source to enhance gene electrotransfer.Bioelectrochemistry (Amsterdam, Netherlands) · 2015Article
- Optimization of a plasma facilitated DNA delivery method.Bioelectrochemistry (Amsterdam, Netherlands) · 2015Article
- Electroporation-mediated gene delivery.Advances in genetics · 2015Article
- A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.Human vaccines & immunotherapeutics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The magnitude of the immune response to a DNA vaccine depends on three criteria--the optimized vector design, the use of a suitable adjuvant and the successful delivery and subsequent expression of the plasmid in the target tissue. In vivo electroporation (EP) has proved to be particularly effective in efficiently delivering DNA immunogens to the muscle and the skin, and indeed several devices have entered into human clinical trials. Here, we report on a novel concept of DNA delivery to the dermal tissue using a minimally invasive EP device, which is powered using low-voltage parameters. We show that this prototype device containing a novel 4 × 4-electrode array results in robust and reproducible transfection of dermal tissue and subsequent antigen expression at the injection site. Using DNA encoding for NP and M2e influenza antigens, we further show induction of potent cellular responses in a mouse model as measured by antigen-specific T-cell ELISpot assays. Importantly, 100% of the immunized animals were protected when challenged with VN/1203/04 (H5N1) strain of influenza. We have also extended our findings to a guinea-pig model and demonstrated induction of HI titers greater than 1:40 against a pandemic novel H1N1 virus showing proof of concept efficacy for DNA delivery with the prototype device in a broad spectrum of species and using multiple antigens. Finally, we were able to generate protective HI titers in macaques against the same novel H1N1 strain. Our results suggest that the minimally invasive dermal device may offer a safe, tolerable and efficient method to administer DNA vaccinations in a prophylactic setting, and thus potentially represents an important new option for improved DNA vaccine delivery in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.